Blog
US Bill Threatens China’s Biotech Industry
📰 WuXi Bio's shares plummet as US 🇺🇸 introduces bill to safeguard its biotech industry from China's 🇨🇳 intellectual property theft.
Alvotech’s Groundbreaking AVT03 Study: A Game-Changer in Osteoporosis Treatment
🔬 Alvotech SA reported positive results from a study of AVT03, a biosimilar candidate for osteoporosis treatment.
Danish Giants Merge to Create Novonesis – Revolutionizing Biosolutions for a Sustainable Future
📢 Danish companies Novozymes AS and Chr. Hansen Holding AS merge to form Novonesis, aiming for a healthier, sustainable future. 💰🌿
Biopharmaceutical Giant Invests $223m to Boost Singapore Plant Capacity!
AbbVie 💰 invests $223m to 🚀 expand Singapore 🌿 plant, boosting capacity to meet 🌎 demand for drugs. 💉🔬
Revolutionary Kyverna Cuts CAR-T Production to 3 Days
📰 CAR-T, a gamechanger in cancer treatment, could revolutionize patient access and save lives with Kyverna's 3-day process. 💉🔬
Revolutionary Biotech Breakthroughs: Restoring Hearing CAR T DNA Meds Nvidia Recursion
📰 Restoring Hearing Loss, CAR T Manufacturing, DNA-Based Medicines, Nvidia and Recursion; Eric Topol delves into biotech advancements. 🦻🧬💊💻🔍
Revolutionary Startup Aims to Transform Cell and Gene Therapies
📰 Frustration with CDMOs fuels ambition for advanced therapy startup GDMC, offering end-to-end solutions for cell and gene therapies. 💡💪🌱🧬
Scientists Create Miracle Enzyme that Destroys Siloxane!
📰 Arnold Lab Uses Directed Evolution to Create Siloxane-Busting Enzyme 🔎 Researchers develop enzyme to break down harmful compounds, reducing environmental impact. 💪🌱
Breakthrough: Affordable Customised Albumin Revolutionizes Therapeutics
📅 January 22, 2024. Demand for animal-free recombinant albumin has led to high prices, limiting access to affordable vaccines and monoclonal antibodies. New technologies are increasing production and expanding its use beyond therapeutics to skincare. Albumin is widely used in diagnostics, medical devices, and regenerative medicine. Patent protections and limited suppliers have created shortages. Lower quality albumin is affordable but presents manufacturing and regulatory issues. Customised strains of baker's yeast are now enabling the production of high-quality, affordable albumin. This could accelerate research and unleash the full potential of albumin. ✨🧪💉🌿🔬💊📈
Sandoz Acquires Lucentis for $170 Million Boosting Ophthalmology Portfolio and Expanding Global Access
📰 Sandoz acquires Coherus' Lucentis for $170m, expanding its ophthalmology portfolio. 💰 Lucentis treats eye diseases worldwide.
